Inventor
SATIJN DAVID
NL43 patents
⚠️ This page may combine multiple inventors who share the name “SATIJN DAVID”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
GENMAB AS
25 patentsUS11440966B2Sep 13, 2022
Multispecific antibodies against CD40 and CD137
GENMAB AS12 citations94
US10544220B2Jan 28, 2020
Bispecific antibodies against CD3 and CD20
GENMAB AS18 citations93
US11091557B2Aug 17, 2021
Methods of producing multispecific antibodies against CD40 and CD137
GENMAB AS10 citations85
US11084882B2Aug 10, 2021
Multispecific antibodies against CD40 and CD137
GENMAB AS8 citations84
US10512688B2Dec 24, 2019
Antibodies binding AXL
GENMAB AS4 citations83
US10500276B2Dec 10, 2019
Antibodies binding AXL
GENMAB AS4 citations83
US10201607B2Feb 12, 2019
Antibodies binding AXL
GENMAB AS7 citations83
US9492565B2Nov 15, 2016
Human antibody drug conjugates against tissue factor
GENMAB AS7 citations82
US12077596B2Sep 3, 2024
Multispecific antibodies against CD40 and CD137
GENMAB AS2 citations73
US11939388B2Mar 26, 2024
Multispecific antibodies against CD40 and CD137
GENMAB AS2 citations73
US11046771B2Jun 29, 2021
Monoclonal antibodies against HER2
GENMAB AS2 citations72
US10765743B2Sep 8, 2020
Antibodies binding AXL
GENMAB AS3 citations72
US11459395B2Oct 4, 2022
Binding agents binding to PD-L1 and CD137 and use thereof
GENMAB AS1 citations71
US11130819B2Sep 28, 2021
Antibodies
GENMAB AS1 citations70
US11008399B2May 18, 2021
Antibodies
GENMAB AS2 citations70
US12589150B2Mar 31, 2026
Antibodies binding AXL
GENMAB AS0 citations62
US12570751B2Mar 10, 2026
Binding agents binding to PD-L1 and CD137 and use thereof
GENMAB AS0 citations61
US11091553B2Aug 17, 2021
Monoclonal antibodies against HER2
GENMAB AS1 citations61
US10968280B2Apr 6, 2021
Binding agents binding to PD-L1 and CD137 and use thereof
GENMAB AS1 citations61
US10793640B2Oct 6, 2020
Monoclonal antibodies against HER2 epitope
GENMAB AS1 citations61
US11970544B2Apr 30, 2024
Antibodies
GENMAB AS0 citations59
US11814437B2Nov 14, 2023
Antibodies binding to CD30 and CD3
GENMAB AS0 citations57
US11261254B1Mar 1, 2022
Antibodies
GENMAB AS0 citations55
US12410258B2Sep 9, 2025
Antibodies capable of binding to OX40, variants thereof and uses thereof
GENMAB AS0 citations53
US12351650B2Jul 8, 2025
Antibodies binding to fibroblast activation protein alpha and death receptor 4
GENMAB AS0 citations49
H LUNDBECK AS
11 patentsUS10800836B2Oct 13, 2020
Agents, uses and methods for the treatment of synucleinopathy
H LUNDBECK AS10 citations92
US10647763B2May 12, 2020
Agents, uses and methods for the treatment of synucleinopathy
H LUNDBECK AS9 citations92
US10647764B2May 12, 2020
Agents, uses and methods for the treatment of synucleinopathy
H LUNDBECK AS9 citations92
US10640554B2May 5, 2020
Agents, uses and methods for the treatment of synucleinopathy
H LUNDBECK AS9 citations92
US10364285B2Jul 30, 2019
Antibodies for the treatment of synucleinopathy
H LUNDBECK AS13 citations92
US10358482B2Jul 23, 2019
Antibodies for the treatment of synucleinopathy
H LUNDBECK AS11 citations92
US10358484B2Jul 23, 2019
Antibodies for the treatment of synucleinopathy
H LUNDBECK AS13 citations92
US10358483B2Jul 23, 2019
Antibodies for the treatment of synucleinopathy
H LUNDBECK AS13 citations92
US11542323B2Jan 3, 2023
Agents, uses and methods for the treatment of synucleinopathy
H LUNDBECK AS6 citations85
US11524995B2Dec 13, 2022
Agents, uses and methods for the treatment of synucleinopathy
H LUNDBECK AS6 citations85
US11421024B2Aug 23, 2022
Agents, uses and methods for the treatment of synucleinopathy
H LUNDBECK AS6 citations85
BioNTech SE
3 patentsUS12421319B2Sep 23, 2025
Binding agents that bind OX40 (CD134) and method of use thereof to treat disease
BioNTech SE0 citations62
US11814411B2Nov 14, 2023
Nucleic acid molecules encoding binding agents to CD40 and 4-1BB (CD137)
BioNTech SE0 citations62
US10927181B2Feb 23, 2021
Agonistic tumor necrosis factor (TNF) receptor binding agents
BioNTech SE0 citations62